Ocugen (OCGN)
(Delayed Data from NSDQ)
$1.75 USD
-0.03 (-1.69%)
Updated May 24, 2024 03:59 PM ET
After-Market: $1.74 -0.01 (-0.57%) 7:58 PM ET
2-Buy of 5 2
F Value C Growth B Momentum D VGM
Brokerage Reports
0 items in cart
Ocugen, Inc. [OCGN]
Reports for Purchase
Showing records 101 - 120 ( 121 total )
Company: Ocugen, Inc.
Industry: Medical - Biomedical and Genetics
COVAXIN Phase 3 Interim Efficacy Appears Competitive - Raising PT to $10.
Provider: Roth Capital Partners, Inc.
Analyst: JALLAH Z
Company: Ocugen, Inc.
Industry: Medical - Biomedical and Genetics
Positive COVAXIN News Boosts U.S. Opportunity; Higher $12 PT; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: Ocugen, Inc.
Industry: Medical - Biomedical and Genetics
EMA ODD for OCU400 Is Validating for Its Gene Therapy - Raising PT to $9.
Provider: Roth Capital Partners, Inc.
Analyst: JALLAH Z
Company: Ocugen, Inc.
Industry: Medical - Biomedical and Genetics
Company: Ocugen, Inc.
Industry: Medical - Biomedical and Genetics
A new COVID-19 Vaccine on the Horizon; Upgrade to Buy with a $4.50 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: Ocugen, Inc.
Industry: Medical - Biomedical and Genetics
Company: Ocugen, Inc.
Industry: Medical - Biomedical and Genetics
COVAXIN Agreement with Bharat Is Very Favorable - Raising PT to $8
Provider: Roth Capital Partners, Inc.
Analyst: JALLAH Z
Company: Ocugen, Inc.
Industry: Medical - Biomedical and Genetics
Company: Ocugen, Inc.
Industry: Medical - Biomedical and Genetics
Who''s Who of Virology Joining the SAB Hints at COVAXIN''s Solid Potential
Provider: Roth Capital Partners, Inc.
Analyst: JALLAH Z
Company: Ocugen, Inc.
Industry: Medical - Biomedical and Genetics
Company: Ocugen, Inc.
Industry: Medical - Biomedical and Genetics
Telegraphing Entry Into War Against COVID-19; Limited Clarity; Reiterate Neutral
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: Ocugen, Inc.
Industry: Medical - Biomedical and Genetics
Ocugen to Co-Develop and Bring Bharat''s COVID Vaccine to the U.S. Market
Provider: Roth Capital Partners, Inc.
Analyst: JALLAH Z
Company: Ocugen, Inc.
Industry: Medical - Biomedical and Genetics
Company: Ocugen, Inc.
Industry: Medical - Biomedical and Genetics
We initiate coverage of Ocugen with a Buy rating and $1 PT.
Provider: Roth Capital Partners, Inc.
Analyst: JALLAH Z
Company: Ocugen, Inc.
Industry: Medical - Biomedical and Genetics
Awaiting Start of Clinical Programs; Reiterate Neutral
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: Ocugen, Inc.
Industry: Medical - Biomedical and Genetics
OCU400 Remains on Track to Enter Clinic; Reiterate Neutral
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: Ocugen, Inc.
Industry: Medical - Biomedical and Genetics
OCU300 Program Discontinued; Lack of Near-term Catalysts; Downgrade to Neutral
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: Ocugen, Inc.
Industry: Medical - Biomedical and Genetics
OCU300 Phase 3 Topline by YE2020; No Impact From COVID-19; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: Ocugen, Inc.
Industry: Medical - Biomedical and Genetics
OCU300 Phase 3 Readout Not Impacted by COVID-19; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: Ocugen, Inc.
Industry: Medical - Biomedical and Genetics
We are sending out a reminder about our 33rd Annual Conference
Provider: Roth Capital Partners, Inc.
Analyst: Research Department